Table 6

In this guide

In this guide

- 1. Table 3 Annex A
- 2. Table 4 Annex A
- 3. Table 5 Annex A
- 4. Table 6 Annex A
- 5. Table 7 Annex A
- 6. Table 8 Annex A
- 7. Table 9 Annex A
- 8. Table 10 Annex A
- 9. Table 11 Annex A
- 10. Table 12 Annex A
- 11. Table 13 Annex A
- 12. Table 14 Annex A
- 13. Table 15 Annex A
- 14. Table 16 Annex A
- 15. Table 17 Annex A
- 16. Table 18 Annex A
- 17. Table 19 Annex A
- 18. Table 20 Annex A
- 19. Table 21 Annex A

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Table 6 Acute toxicity studies for PFSAs - PFOS

*Derived by contractor; ** calculated according to EFSA. (2012); NR – not reported; NA – not applicable; # - no. of animals studied per endpoint differs to the no. of animals treated.

Substance Strain & / CAS no. / species / purity / sex / no. reference of animals	Dose (mg/kg bw/day) / vehicle / route of admin / duration / Guideline (GL) study / Good Laboratory Practice (GLP) status	PFAS concentration (μg/mL / μg/g)	~~~~	Published NOAEL / LOAEL (mg/kg	Study author conclusion
----------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------	---------------------------------------------	------	-----------------------------------------	-------------------------------

At 9 mg/kg bw in males on day 113 (mean ± SD)

				day 113 (mean ± SD)			
			Group 1 and 2: 0 or 9	Serum: 67.7 ± 7.5.	Males:		
PFOS (potassium salt)		Tween® 20 + 5% absolute ethanol in water.	At 9 mg/kg bw in males on day 420, Serum: 14.1 ± 2.0	adverse effects in liver reported. 9 / NA* Females: Females:	There were no treatment related		
	CAS no. Not given 86.9%. Chang et al. (2017)	Cynomolgus monkeys. Male and female 6/sex/dose.	Js Gavage Single dose, animals not sacrificed,	Liver: 7.8 ± No 5.5. adverse effects At 9 mg/kg bw liver in females on reporte day 113 Recove Serum: 68.8 ± 2.5. No adverse	adverse effects in liver reported. Recovery: No adverse effects in liver	9 / NA* Recovery Males: 9 / NA* Y: Females: 9 / NA*	changes in serum liver enzymes during the study.
				Serum: 9.5 ± 4.4			
				Liver: 8.3 ±			

3.3.

			At 14 mg/kg bw/day in males on day			
			50 (mean ± SD)			
			Serum: 104.8 ± 5.2.			
			At 14 mg/kg bw/day in females on day 50			
			Serum: 96.5 ± 6.2.			
		Group 1 and 3:	At 14.8/17.2 bw/day in males on day 295			
		0, 14, 14.8 / 17.2 (male/female) and 11	Serum:141.0 ± 13.1. At 14.8/17.2	Males: No adverse effects in	Males: 14.8 or 17.2 / NA*.	
PFOS (potassiu salt)	m Cynomolgus	0.5% Tween 20 + 5% EtoH.	bw/day in females on day 295 Serum: 147.6	liver	Females: 14.8 or	There were no treatment
CAS no.	monkeys,	Gavage,	± 17.5.	No	17.2 / NA*.	related
Not giver	Male and female,	Single doses on days 43,	At 11 mg/kg	adverse effects in	Recovery	changes in serum liver
86.9%. 4-		288 and 358,	bw in males on day 365	liver reported.	Males:	enzymes
Chang et al. (2017)	6/sex/dose	sacrificed,	Serum:160.8 ±	Recovery:	14.8 or 17.2 / NA*.	during the study.
		Non-GL study GLP not stated.	At 11 mg/kg bw in females	No adverse effects in	Females:	